Methods and compositions for treating skin afflictions

Patent metadata

Field	Value
Publication number	US-11311484-B2
Application number	US-201917052327-A
Country	US
Kind code	B2
Filing date	Apr 30, 2019
Priority date	May 2, 2018
Publication date	Apr 26, 2022
Grant date	Apr 26, 2022

Abstract

The present invention relates to a method for treating skin afflictions in a subject comprising a step of administering said subject with a therapeutically effective amount of small extracellular vesicles (sEV) comprising CD98hc. Inventors have demonstrated that healthy dermal fibroblasts produced and secreted EVs bearing characteristic of exosome-like small EVs (sEVs). They have shown that CD98hc was present at the surface of sEVs, transferred and stabilized at the plasma membrane of recipient cells. They observed that the transferred protein was functional both in vitro and in vivo. Furthermore, injection of sEVs in epidermal CD98hc KO mice exhibiting wound healing defect rescued wound closure in vivo. Thus, their findings reveal that CD98hc contained in EVs could potentially be used in vivo to treat and improve multiple skin afflictions by allowing protein rescue.

First claim

The invention claimed is:

1. A method for treating a skin affliction in a subject comprising a step of administering to said subject a therapeutically effective amount of small extracellular vesicles (sEV) comprising CD98hc.

2. The method according to claim 1 , wherein, the sEV are exosomes.

3. The method according to claim 1 , wherein, the sEV are nanoparticles.

4. The method according to claim 1 , wherein, the sEV are liposomes.

5. The method according to claim 1 , wherein, the administration of sEV is performed by topical administration.

6. The method according to claim 1 , wherein the skin affliction is a wound.

7. The method according to claim 6 wherein the method improves healing of the wound.

8. The method according to claim 6 , wherein subject is an elderly person.

9. The method according to claim 1 , wherein the step of administering is performed in combination with a standard treatment of skin afflictions.

Assignees

• Inst Nat Sante Rech Med
• Univ Cote D'Azur
• Centre Nat Rech Scient
• Univ Nice Sophia Antipolis

Inventors

• Feral Chloé
• Tissot Floriane
• Cailleteau Laurence
• Estrach Soline

Classifications

• A61K35/12

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• A61K9/127 Primary

  Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title

• A61K38/22 Primary

  Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title